Toggle Dropdown
Groups
Announcements
Projects
Ideas
Welcome guest
Log in
Practice
My Requests
All Requests
Drill Partners
Digital games
Projects
Goals
Loading
Loading...
0
0
Lilly's orforglipron helped people maintain weight loss after switching from injectable incretins to oral GLP-1 therapy in first-of-its-kind Phase 3 trial - Eli Lilly
12/18/25 at 11:46am
Organization
Lilly.com
48 words
0
Comments
The Investor Relations website contains information about Eli Lilly and Company's business for stockholders, potential investors, and financial analysts.
Business & Industrial
Weight Loss
Pharmaceuticals & Biotech
Drugs & Medications
Company News
You are the first to view
https://investor.lilly.com/news-releases/news-release-details/lillys-orforglipron-helped-people-maintain-weight-loss-after
Create an account
or
login
to join the discussion
Modal title
...
Profile
Loading profile
Loading...